Why JP Morgan Cazenove Has Just Restated Their Neutral Rating For Abcam PLC (LON:ABC) Shares

Abcam plc (LON:ABC) Logo

Abcam PLC (LON:ABC) Rating Reaffirmed

This Morning, JP Morgan Cazenove reiterated their Neutral rating on Abcam PLC (LON:ABC) shares in an analyst report revealed to clients and investors.

Abcam plc (LON:ABC) Ratings Coverage

Among 4 analysts covering Abcam PLC (LON:ABC), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Abcam PLC has GBX 1640 highest and GBX 1230 lowest target. GBX 1436.67’s average target is 17.33% above currents GBX 1224.5 stock price. Abcam PLC had 17 analyst reports since July 12, 2018 according to SRatingsIntel. The stock of Abcam plc (LON:ABC) earned “Hold” rating by Peel Hunt on Wednesday, October 3. Numis Securities maintained the stock with “Hold” rating in Tuesday, September 11 report. The firm has “Hold” rating by Peel Hunt given on Monday, September 10. The company was maintained on Thursday, July 12 by Peel Hunt. Peel Hunt upgraded the shares of ABC in report on Wednesday, January 9 to “Buy” rating. The company was maintained on Wednesday, September 19 by Peel Hunt. The rating was maintained by Berenberg on Tuesday, January 8 with “Buy”. The rating was maintained by Peel Hunt with “Hold” on Thursday, November 1. As per Wednesday, August 1, the company rating was maintained by Peel Hunt. The stock has “Hold” rating by Peel Hunt on Thursday, December 6.

The stock decreased 2.51% or GBX 31.5 during the last trading session, reaching GBX 1224.5. About 330,130 shares traded. Abcam plc (LON:ABC) has 0.00% since January 10, 2018 and is . It has by 0.00% the S&P500.

Analysts await Abcam plc (LON:ABC) to report earnings on January, 31 before the open. They expect $1.51 earnings per share, down 2.58 % or $0.04 from last year’s $1.55 per share. ABC’s profit will be $3.09M for 202.73 P/E if the $1.51 EPS becomes a reality. After $1.45 actual earnings per share reported by Abcam plc for the previous quarter, Wall Street now forecasts 4.14 % EPS growth.

Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company has market cap of 2.51 billion GBP. The firm primarily offers primary and secondary antibodies, biochemicals, isotype controls, flow cytometry multi-color selectors, kits, loading controls, lysates, peptides, proteins, slides, tags and cell markers, and tools and reagents. It has a 40.55 P/E ratio. The Company’s products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics and nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells, as well as in drug discovery services and products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.